TISIDB

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus, nucleoplasm.
Domain	PF00076 RNA recognition motif. (a.k.a. RRM PF08080 RNPHF zinc finger
Function	This protein is a component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complexes which provide the substrate for the processing events that pre-mRNAs undergo before becoming functional, translatable mRNAs in the cytoplasm. Mediates pre-mRNA alternative splicing regulation. Inhibits, together with CUGBP1, insulin receptor (IR) pre-mRNA exon 11 inclusion in myoblast. Binds to the IR RNA. Binds poly(RG).

> Gene Ontology [ TOP ]
Biological Process	GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000398 mRNA splicing, via spliceosome GO:0006397 mRNA processing GO:0008380 RNA splicing GO:0008543 fibroblast growth factor receptor signaling pathway GO:0043484 regulation of RNA splicing GO:0044344 cellular response to fibroblast growth factor stimulus GO:0071774 response to fibroblast growth factor
Molecular Function	GO:0003727 single-stranded RNA binding GO:0008187 poly-pyrimidine tract binding GO:0008266 poly(U) RNA binding
Cellular Component	GO:0005681 spliceosomal complex GO:0071013 catalytic step 2 spliceosome

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-6803529: FGFR2 alternative splicing R-HSA-74160: Gene Expression R-HSA-72203: Processing of Capped Intron-Containing Pre-mRNA R-HSA-162582: Signal Transduction R-HSA-190236: Signaling by FGFR R-HSA-5654738: Signaling by FGFR2 R-HSA-72172: mRNA Splicing R-HSA-72163: mRNA Splicing - Major Pathway

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between HNRNPH1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of HNRNPH1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: 1.06; FDR: 0.014300	Sensitive to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of HNRNPH1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.196	0.316
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.134	0.967
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.238	0.918
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.379	0.202
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.37	0.893
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.395	0.913
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.089	0.855
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.14	0.952
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.016	0.995
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.301	0.905
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.651	0.858
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.048	0.319

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of HNRNPH1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HNRNPH1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HNRNPH1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HNRNPH1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HNRNPH1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of HNRNPH1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between HNRNPH1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	HNRNPH1
Name	heterogeneous nuclear ribonucleoprotein H1 (H)
Aliases	hnRNPH; HNRPH1; HNRPH; hnRNP H; Heterogeneous nuclear ribonucleoprotein H
Chromosomal Location	5q35.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting HNRNPH1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting HNRNPH1.

ID	Name	Drug Type	Targets	#Targets
DB09130	Copper	Small Molecule	A1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......	141

Browse HNRNPH1